Cetuximab: its unique place in head and neck cancer treatment

Pol Specenier, Jan B Vermorken Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium Abstract: Head and neck cancer is the sixth most common cancer worldwide. At present, globally about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are diagnosed eac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Specenier P, Vermorken JB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/63dc4cfc92194dbf86985b7256dbdf08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63dc4cfc92194dbf86985b7256dbdf08
record_format	dspace
spelling	oai:doaj.org-article:63dc4cfc92194dbf86985b7256dbdf082021-12-02T03:07:00ZCetuximab: its unique place in head and neck cancer treatment1177-54751177-5491https://doaj.org/article/63dc4cfc92194dbf86985b7256dbdf082013-04-01T00:00:00Zhttp://www.dovepress.com/cetuximab-its-unique-place-in-head-and-neck-cancer-treatment-a12752https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Pol Specenier, Jan B Vermorken Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium Abstract: Head and neck cancer is the sixth most common cancer worldwide. At present, globally about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are diagnosed each year. The epidermal growth factor receptor (EGFR) is almost invariably expressed in SCCHN. Overexpression of the EGFR is a strong and independent unfavorable prognostic factor in SCCHN. Cetuximab is a chimeric monoclonal antibody, which binds with high affinity to the extracellular domain of the human EGFR, blocking ligand binding, resulting in inhibition of the receptor function. It also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody dependent cell-mediated cytotoxicity). The addition of cetuximab to radiotherapy (RT) improves locoregional control and survival when compared to RT alone. The addition of cetuximab to platinum-based chemoradiation (CRT) is feasible but does not lead to an improved outcome. Cetuximab plus RT has never been compared prospectively to CRT, which therefore remains the standard treatment for patients with locoregionally advanced SCCHN for whom surgery is not considered the optimal treatment, provided they can tolerate CRT. The addition of cetuximab to platinum-based chemotherapy prolongs survival in patients with recurrent or metastatic SCCHN. The combination of a platinum-based regimen and cetuximab should be considered as the standard first line regimen for patients who can tolerate this treatment. Keywords: SCCHN, cetuximab, recurrent metastatic, locoregionally advanced, chemoradiationSpecenier PVermorken JBDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 77-90 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Specenier P Vermorken JB Cetuximab: its unique place in head and neck cancer treatment
description	Pol Specenier, Jan B Vermorken Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium Abstract: Head and neck cancer is the sixth most common cancer worldwide. At present, globally about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are diagnosed each year. The epidermal growth factor receptor (EGFR) is almost invariably expressed in SCCHN. Overexpression of the EGFR is a strong and independent unfavorable prognostic factor in SCCHN. Cetuximab is a chimeric monoclonal antibody, which binds with high affinity to the extracellular domain of the human EGFR, blocking ligand binding, resulting in inhibition of the receptor function. It also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody dependent cell-mediated cytotoxicity). The addition of cetuximab to radiotherapy (RT) improves locoregional control and survival when compared to RT alone. The addition of cetuximab to platinum-based chemoradiation (CRT) is feasible but does not lead to an improved outcome. Cetuximab plus RT has never been compared prospectively to CRT, which therefore remains the standard treatment for patients with locoregionally advanced SCCHN for whom surgery is not considered the optimal treatment, provided they can tolerate CRT. The addition of cetuximab to platinum-based chemotherapy prolongs survival in patients with recurrent or metastatic SCCHN. The combination of a platinum-based regimen and cetuximab should be considered as the standard first line regimen for patients who can tolerate this treatment. Keywords: SCCHN, cetuximab, recurrent metastatic, locoregionally advanced, chemoradiation
format	article
author	Specenier P Vermorken JB
author_facet	Specenier P Vermorken JB
author_sort	Specenier P
title	Cetuximab: its unique place in head and neck cancer treatment
title_short	Cetuximab: its unique place in head and neck cancer treatment
title_full	Cetuximab: its unique place in head and neck cancer treatment
title_fullStr	Cetuximab: its unique place in head and neck cancer treatment
title_full_unstemmed	Cetuximab: its unique place in head and neck cancer treatment
title_sort	cetuximab: its unique place in head and neck cancer treatment
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/63dc4cfc92194dbf86985b7256dbdf08
work_keys_str_mv	AT specenierp cetuximabitsuniqueplaceinheadandneckcancertreatment AT vermorkenjb cetuximabitsuniqueplaceinheadandneckcancertreatment
_version_	1718401920885850112

Cetuximab: its unique place in head and neck cancer treatment

Ejemplares similares